[VIRTUAL] EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9: RESULTS OF PHASE 3 TRIAL OF CEMIPLIMAB VS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN RECURRENT/METASTATIC CERVICAL CARCINOMA

[VIRTUAL] EFFICACY AND SAFETY OF NIRAPARIB MAINTENANCE TREATMENT IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER AFTER SHORTER OR LONGER CHEMOTHERAPY: A POST HOC SUBGROUP ANALYSIS

[VIRTUAL] COST-EFFECTIVENESS OF DOSTARLIMAB IN ADVANCED RECURRENT DEFICIENT MISMATCH REPAIR ENDOMETRIAL CANCER PATIENTS

[VIRTUAL] RANDOMIZED PHASE 3 STUDY OF LENVATINIB PLUS PEMBROLIZUMAB FOR ADVANCED ENDOMETRIAL CANCER (AEC): SUBGROUP ANALYSIS OF PATIENTS WITH DNA MISMATCH REPAIR DEFICIENT (DMMR) TUMORS

[VIRTUAL] ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR–DEFICIENT OR PROFICIENT–CANCER BY PRIOR THERAPY: RESULTS FROM THE GARNET STUDY

[VIRTUAL] TISOTUMAB VEDOTIN (TV) + BEVACIZUMAB OR PEMBROLIZUMAB OR CARBOPLATIN IN RECURRENT/METASTATIC CERVICAL CANCER (R/MCC): PHASE 1B/2 ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY DOSE-ESCALATION RESULTS

[VIRTUAL] EFFICACY AND SAFETY OF SOCAZOLIMAB IN RECURRENT OR METASTATIC CERVICAL CANCER: RESULTS FROM THE PHASE I TRIAL FOLLOWED BY AN EXPANSION STUDY

[VIRTUAL] CLINICAL AND MOLECULAR CHARACTERISTICS OF ARIEL3 PATIENTS WHO DERIVED EXCEPTIONAL BENEFIT FROM RUCAPARIB MAINTENANCE TREATMENT FOR HIGH-GRADE OVARIAN CANCER (HGOC)

[VIRTUAL] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer - final analysis

[VIRTUAL] A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775

[VIRTUAL] Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase 3 study

[VIRTUAL] Adjuvant chemotherapy following chemo-radiation as primary treatment for locally advanced cervical cancer compared to chemo-radiation alone: The randomised phase 3 OUTBACK Trial

[VIRTUAL] PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

[VIRTUAL] EUROPEAN NETWORK FOR GYNAECOLOGICAL ONCOLOGICAL TRIAL (ENGOT)- CX11/GYNECOLOGIC ONCOLOGY GROUP (GOG) 3047/KEYNOTE-A18: PHASE 3 TRIAL OF PEMBROLIZUMAB PLUS CHEMORADIOTHERAPY IN HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER